What Does Wall Street Think About Savara Inc. (SVRA)?

Savara Inc. (NASDAQ:SVRA) is one of the best stocks under $5 with highest upside potential. On October 23, Citizens JMP lifted its price target on Savara Inc. (NASDAQ:SVRA) to $11 from $8 while keeping an Outperform rating on the shares.

The firm told investors in a research note that its pulmonologist survey shows solid demand for Molbreevi, with 60% of those surveyed expressing an inclination to use it. This, according to Citizens JMP, should mean blockbuster sales, with Savara Inc. (NASDAQ:SVRA) set to resubmit its application for Molbreevi in December.

Additionally, Savara Inc. (NASDAQ:SVRA) was initiated with a new Buy rating by LifeSci Capital analyst Francois Brisebois on October 14, who also based the optimistic outlook on Molbreevi’s promising potential. It is focused on the treatment of autoimmune pulmonary alveolar proteinosis (aPAP), a rare and chronic disease that currently does not have approved treatments in the EU and US, with the sole exception of whole lung lavage.

The analyst thus stated that expert feedback shows that Molbreevi can attain blockbuster status in the US market, with its unique formulation as a large inhaled biologic shielding it from competition from biosimilars.

Savara Inc. (NASDAQ:SVRA) is a clinical-stage pharmaceutical company that develops and commercializes novel therapies for serious or life-threatening rare respiratory diseases. The company’s program includes molgramostim, an inhaled formulation of recombinant human GM-CSF being developed to treat autoimmune pulmonary alveolar proteinosis.

While we acknowledge the potential of SVRA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.